CoChat
Sign Up
Cited by 7HIV-related health complications and treatmentsDiabetes, Cardiovascular Risks, and LipoproteinsPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: A Randomized Trial

van Wijk, Jeroen P.H., de Koning, Eelco J.P., Cabezas, Manuel Castro, op't Roodt, Jos, Joven, Jorge, Rabelink, Ton J., Hoepelman, Andy I.·2005·Annals of Internal Medicine
DOI 10.7326/0003-4819-143-5-200509060-00009
Open this paper in CoChat — free account

Abstract

Background: The use of antiretroviral combination therapy in HIV has been associated with lipodystrophy and cardiovascular risk factors. Objective: To compare the effects of the peroxisome proliferator–activated receptor-γ agonist rosiglitazone and metformin for treating HIV lipodystrophy. Design: An open, randomized, 6-month clinical trial. Setting: University Medical Center, Utrecht, the Netherlands. Patients: 39 HIV-infected men with lipodystrophy. Intervention: Rosiglitazone, 8 mg/d, or metformin, 2 g/d. Measurements: Insulin sensitivity estimated by the oral glucose tolerance test, subcutaneous and visceral abdominal fat measured by single-slice computed tomography, endothelial function measured by flow-mediated vasodilation, and fasting plasma measurements. Two patients in the metformin group withdrew from the study. Complete case analysis was performed. Results: Compared with metformin, rosiglitazone increased subcutaneous abdominal fat (between-treatment change from baseline, 27 cm2 [95% CI, 7 cm2 to 46 cm2]) and visceral abdominal fat (between-treatment change from baseline, 24 cm2 [CI, 6 cm2 to 51 cm2]). The area under the curve for insulin after the oral glucose tolerance test decreased similarly with both agents, but only rosiglitazone increased adiponectin levels. Metformin showed greater benefits on fasting lipid profile than rosiglitazone. Flow-mediated vasodilation statistically significantly increased with metformin (mean change, 1.5% [CI, 0.4% to 3.3%]) and not with rosiglitazone (mean change, 0.7% [CI, −1.1% to 2.7%]). The metformin versus rosiglitazone increases did not statistically differ. Rosiglitazone and metformin did not change C-reactive protein levels. Limitations: This small trial was not blinded or placebo-controlled and did not measure clinical outcomes. Conclusions: The findings emphasize the importance of individualized care in HIV-infected patients. Although rosiglitazone may partly correct lipoatrophy, metformin improves visceral fat accumulation, fasting lipid profile, and endothelial function.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-143-5-200509060-00009

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

Sorted by citations

See all 7

Related

Metadata

Authors
van Wijk, J. P. H., de Koning, E. J. P., Cabezas, M. C., op't Roodt, J., Joven, J., Rabelink, T. J., & Hoepelman, A. I.
Affiliations
  • From University Medical Center, Utrecht, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands; St. Franciscus Gasthuis, Rotterdam, the Netherlands; and Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Reus, Spain.
  • Leiden University Medical Center (NL)
ORCID
Venue
Annals of Internal Medicine
Publisher
American College of Physicians
Published
2005-09-06
Volume
143
Issue
5
Pages
337-346
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
DOI
10.7326/0003-4819-143-5-200509060-00009
OpenAlex
W1490891702
Cited by
3
References
52
FWCI
0.74
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
Annals of Internal Medicine (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
HIV lipodystrophy, rosiglitazone, metformin, peroxisome proliferator-activated receptor gamma agonists, insulin sensitivity, visceral fat, subcutaneous abdominal fat, adiponectin, endothelial function, flow-mediated dilation, fasting lipid profile, C-reactive protein, antiretroviral therapy adverse effects, lipoatrophy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review